

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Sanfilippo, Roberta		POSITION TITLE Medical Oncologist, Sarcoma Service, Oncology Department, IRCCS Istituto Nazionale Tumori, Milan Italy	
eRA COMMONS USER NAME (credential, e.g., agency login)			
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
Medical Oncology trainee at Fondazione IRCCS Istituto Nazionale Tumori – Adult Mesenchymal Tumours and Rare Cancers Prof. Paolo G. Casali, Istituto Nazionale Tumori, Milan (Italy), Italy	Oncologist	11/2007	Adult soft tissue sarcoma and GIST
University of Palermo, Italy	Degree in medicine	10/2003	Faculty of medicine

A. Personal Statement

Dr Sanfilippo is a medical oncologist dedicated at adult patients with sarcoma in the Oncology Unit directed by professor Paolo Casali at Istituto Nazionale Tumori, Milan, where she completed her residency training. She is involved in all the institutional research activities on soft tissue and bone sarcoma, and GIST, which include development of new preclinical models of sarcomas, identification of new targets and new anticancer treatments for specific sarcoma subtypes, studies on the immune-profile of sarcomas as well as on mechanisms of resistance to therapy, clinical studies on neoadjuvant therapies in extremities and retroperitoneal soft tissue sarcoma, and on metastatic bone and soft tissue sarcomas. She is particularly dedicated to liposarcoma, leiomyosarcoma subtypes and uterine sarcoma. She is the leader of the Gynecological working group of the international leiomyosarcoma round-table (an international research group dedicated to leiomyosarcomas). She is the Principal Investigator of Italian and International trials on sarcoma and uterine sarcoma. She is one coordinator of the Italian Network on Rare Tumors. She collaborates with several sarcoma Patients Advocacy Groups, among which in particular the Leiomyosarcoma Foundation. She is in the editorial board of the journal Anticancer Drug from 2016.

B. Positions and Honors

Positions and Employment

2007-present Medical Oncologist at “Fondazione IRCCS Istituto Nazionale Tumori” – Adult Mesenchymal Tumours directed by professor Paolo Casali

2004-2007 Clinical and research fellow at “Fondazione IRCCS Istituto Nazionale Tumori” – Adult Mesenchymal Tumours directed by professor Paolo Casali

Other Experience and Professional Memberships

2007-present Coordinator of Italian Rare Cancer Network

2016-present Member of ESMO

2016-present Member of the Editorial Board of Anticancer drug

2019-present Scientific coordinator of the Gynecological Leiomyosarcoma round table

C. Contributions to Science

Selected Peer-reviewed Publications

1: Baia M, Drohan A, Radaelli S, Callegaro D, Colombo C, Borghi A, Pasquali S, Sanfilippo R, Sangalli C, Morosi C, Fiore M, Gronchi A. Resection of Primary Leiomyosarcoma of the Inferior Vena Cava and Reconstruction with a Cadaveric Homograft. *Ann Surg Oncol*. 2025 Apr;32(4):2979-2980. doi: 10.1245/s10434-025-16911-y. Epub 2025 Feb 5. PMID: 39909990.

2: Craparotta I, Mannarino L, Zadro R, Ballabio S, Marchini S, Pavesi G, Russo M, Renne SL, Meroni M, Ponzo M, Bello E, Sanfilippo R, Casali PG, D'Incalci M, Frapolli R. Mechanism of efficacy of trabectedin against myxoid liposarcoma entails detachment of the FUS-DDIT3 transcription factor from its DNA binding sites. *J Exp Clin Cancer Res*. 2024 Nov 26;43(1):309. doi: 10.1186/s13046-024-03228-z. PMID: 39587691; PMCID: PMC11590625.

3: Pasquali S, Iadecola S, Vanzulli A, Infante G, Bologna M, Corino V, Greco G, Vigorito R, Morosi C, Beretta A, Percio S, Vallacchi V, Collini P, Sanfilippo R, Fabbroni C, Stacchiotti S, Fiore M, Huang P, Benelli M, Mainardi L, Miceli R, Gronchi A, Callegaro D. Radiomic features of primary retroperitoneal sarcomas: a prognostic study. *Eur J Cancer*. 2024 Dec;213:115120. doi: 10.1016/j.ejca.2024.115120. Epub 2024 Nov 9. PMID: 39541785.

4: Tseng WW, Barretta F, Tucci F, Barisella M, Radaelli S, Colombo C, Callegaro D, Morosi C, Sanfilippo R, Fabbroni C, Stacchiotti S, Sun SH, Collini P, Fiore M, Gronchi A. Pleomorphic Liposarcoma of the Extremity and Trunk: Multimodality Therapy for Some but Not All? *J Surg Oncol*. 2024 Sep 27. doi: 10.1002/jso.27884. Epub ahead of print. PMID: 39328165.

5: Ray-Coquard I, Casali PG, Croce S, Fennessy FM, Fischerova D, Jones R, Sanfilippo R, Zapardiel I, Amant F, Blay JY, Martin-Broto J, Casado A, Chiang S, Dei Tos AP, Haas R, Hensley ML, Hohenberger P, Kim JW, Kim SI, Meydanli MM, Pautier P, Abdul Razak AR, Sehouli J, van Houdt W, Planchamp F, Friedlander M. ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas. *Int J Gynecol Cancer*. 2024 Oct 7;34(10):1499-1521. doi: 10.1136/ijgc-2024-005823. PMID: 39322612.

6: Baia M, Zanframundo C, Ljevar S, Della Valle S, Misotti A, Rampello NN, Proto P, Callegaro D, Colombo C, Radaelli S, Sanfilippo R, Sangalli C, Morosi C, Pasquali S, Miceli R, Gronchi A, Fiore M. Preoperative nutritional support to tackle morbidity in multivisceral resection for retroperitoneal sarcoma. Early outcomes from a novel nutritional prehabilitation program in a prospective cohort. *Eur J Surg Oncol*. 2024 Dec;50(12):108663. doi: 10.1016/j.ejso.2024.108663. Epub 2024 Sep 3. PMID: 39265414.

7: Tseng WW, Barretta F, Fiore M, Colombo C, Radaelli S, Baia M, Morosi C,

Collini P, Sanfilippo R, Fabbroni C, Stacchiotti S, Roberts RF, Callegaro D, Gronchi A. Extent of macroscopic vascular invasion predicts distant metastasis in primary leiomyosarcoma of the inferior vena cava. *J Surg Oncol*. 2024 Dec;130(8):1691-1699. doi: 10.1002/jso.27799. Epub 2024 Aug 19. PMID: 39155701.

8: Fabbroni C, Grignani G, Vincenzi B, Fumagalli E, De Pas TM, Mazzocca A, Pantaleo MA, Brunello A, Baldi GG, Boglione A, Fatigoni S, Berruti A, Giordano M, Marrari A, Dei Tos AP, Alberton AS, Aliberti S, Carlucci L, Rulli E, Casali PG, Sanfilippo R. TRAbectedin in adVanced rETroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group. *ESMO Open*. 2024 Aug;9(8):103667. doi: 10.1016/j.esmoop.2024.103667. Epub 2024 Aug 8. PMID: 39121815; PMCID: PMC11364015.

9: Franza A, Fabbroni C, Pasquali S, Casali PG, Sanfilippo R. New targeted therapies in liposarcoma: state of art and future perspectives. *Curr Opin Oncol*. 2024 Jul 1;36(4):291-296. doi: 10.1097/CCO.0000000000001055. Epub 2024 May 7. PMID: 38726840.

10: Franza A, Gusmaroli E, Fabbroni C, Vigorito R, Pasquali S, Casali PG, Sanfilippo RG. Long-term disease stability with bicalutamide in a man with aggressive angiomyxoma: case report and state of art. *Front Oncol*. 2024 Jan 16;13:1260668. doi: 10.3389/fonc.2023.1260668. PMID: 38298446; PMCID: PMC10829570.

11: Rota S, Franza A, Fabbroni C, Paolini B, Greco FG, Alessi A, Padovano B, Casali P, Sanfilippo R. COL1A1::PDGFB fusion-associated uterine fibrosarcoma: A case report and review of the literature. *Cancer Rep (Hoboken)*. 2024 Feb;7(2):e1969. doi: 10.1002/cnr2.1969. Epub 2024 Jan 26. PMID: 38279510; PMCID: PMC10849982.

12: Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Pizzamiglio S, Verderio P, Fontana V, Donati DM, Palassini E, Sanfilippo R, Bianchi G, Bertuzzi A, Morosi C, Pasquali S, Stacchiotti S, Bagué S, Coindre JM, Miceli R, Dei Tos AP, Casali PG. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG). *J Clin Oncol*. 2024 Mar 10;42(8):898-906. doi: 10.1200/JCO.23.00908. Epub 2024 Jan 17. Erratum in: *J Clin Oncol*. 2024 Aug 10;42(23):2838. doi: 10.1200/JCO-24-01287. PMID: 38232337.

13: Mantiero M, Bini M, Polignano M, Porcu L, Sanfilippo R, Fabbroni C, Parma G, Lapresa M, Calidona C, Silvestri C, Franza A, Raspagliesi F, Colombo N, Ducceschi M. A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety. *Cancers (Basel)*. 2023 Dec 30;16(1):192. doi: 10.3390/cancers16010192. PMID: 38201619; PMCID: PMC10777896.

14: Ng D, Bertrand A, Sanfilippo R, Callegaro D. Deciding individual treatment

for primary retroperitoneal sarcoma. *Expert Rev Anticancer Ther.* 2023 Jul-Dec;23(11):1169-1178. doi: 10.1080/14737140.2023.2266137. Epub 2023 Oct 27. PMID: 37791587.

15: Sanfilippo R, Sbaraglia M, Fabbroni C, Croce S, Ray-Coquard I, Guermazi F, Paolini B, Blanc-Durand F, Lecesne A, Chiappa V, Dei Tos AP, Casali PG. Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal Treatment. *Clin Cancer Res.* 2023 Nov 14;29(22):4679-4684. doi: 10.1158/1078-0432.CCR-23-0692. PMID: 37699075.

16: Sanfilippo R, Hindi N, Cruz Jurado J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón-Perez I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Fabbroni C, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, Martin-Broto J, Gronchi A. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial. *JAMA Oncol.* 2023 May 1;9(5):656-663. doi: 10.1001/jamaoncol.2023.0056. PMID: 36995731; PMCID: PMC10064283.

17: Palmerini E, Sanfilippo R, Grignani G, Buonadonna A, Romanini A, Badalamenti G, Ferraresi V, Vincenzi B, Comandone A, Pizzolorusso A, Brunello A, Gelsomino F, De Pas T, Ibrahim T, Gurrieri L, Grosso F, Zanelli F, Pantaleo MA, Milesi L, Ciuffreda L, Ferrari V, Marchesi E, Quattrini I, Righi A, Setola E, Carretta E, Casali PG, Picci P, Ferrari S. Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a <i>post-hoc</i> analysis. *Front Oncol.* 2022 Dec 8;12:1042479. doi: 10.3389/fonc.2022.1042479. PMID: 36568164; PMCID: PMC9780071.

18: Fiore M, Ljevar S, Pasquali S, Morelli D, Callegaro D, Sanfilippo R, Barisella M, Sangalli C, Miceli R, Gronchi A. Preoperative Neutrophil-to-Lymphocyte Ratio and a New Inflammatory Biomarkers Prognostic Index for Primary Retroperitoneal Sarcomas: Retrospective Monocentric Study. *Clin Cancer Res.* 2023 Feb 1;29(3):614-620. doi: 10.1158/1078-0432.CCR-22-2897. PMID: 36478176.

19: Vincenzi B, Napolitano A, Comandone A, Sanfilippo R, Celant S, Olimpieri PP, Di Segni S, Russo P, Casali PG. Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry. *Int J Cancer.* 2023 Feb 15;152(4):761-768. doi: 10.1002/ijc.34309. Epub 2022 Oct 13. PMID: 36196483; PMCID: PMC10092104.

20: Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, Baldini EH, Benjamin RS, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, D'Angelo SP, Davis EJ, Dei Tos AP, Demicco EG, Desai J, Dileo P, Eriksson M, Gelderblom H, George S, Gladdy RA, Gounder MM, Gupta AA, Haas R, Hayes A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Maestro R, Martin Broto J, Maki RG, Miah AB, Palmerini E, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Strauss SJ, Tap WD, Thomas DM, Trama A, Trent JC, van der Graaf WTA, van Houdt WJ, von Mehren M, Wilky BA, Fletcher CDM, Gronchi A, Miceli R, Wagner AJ. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of

experts on the minimum requirements for the evaluation of activity of systemic treatments. *Cancer Treat Rev.* 2022 Nov;110:102455. doi: 10.1016/j.ctrv.2022.102455. Epub 2022 Aug 18. PMID: 36031697.

21: Sanfilippo R, Hayward RL, Musoro J, Benson C, Leahy MG, Brunello A, Blay JY, Steeghs N, Desar IME, Ali N, Hervieu A, Thway K, Marreaud S, Litiere S, Kasper B. Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). *JAMA Oncol.* 2022 Oct 1;8(10):1420-1425. doi: 10.1001/jamaoncol.2022.3218. PMID: 35980618; PMCID: PMC9389439.

22: Tseng WW, Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Ford SJ, Gonzalez RJ, Gladdy RA, Gyorki DE, Fairweather M, Lee KW, Albertsmeier M, van Houdt WJ, Fau M, Nessim C, Grignani G, Cardona K, Quagliuolo V, Grignol V, Farma JM, Pennacchioli E, Fiore M, Hayes A, Tzanis D, Skoczylas J, Almond ML, Mullinax JE, Johnston W, Snow H, Haas RL, Callegaro D, Smith MJ, Bouhadiba T, Desai A, Voss R, Sanfilippo R, Jones RL, Baldini EH, Wagner AJ, Catton CN, Stacchiotti S, Thway K, Roland CL, Raut CP, Gronchi A; Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. *Ann Surg Oncol.* 2022 Nov;29(12):7335-7348. doi: 10.1245/s10434-022-11864-y. Epub 2022 Jun 29. PMID: 35767103.

23: Stacchiotti S, Van der Graaf WTA, Sanfilippo RG, Marreaud SI, Van Houdt WJ, Judson IR, Gronchi A, Gelderblom H, Litiere S, Kasper B. First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. *Cancer.* 2022 Aug 1;128(15):2932-2938. doi: 10.1002/cncr.34264. Epub 2022 May 13. PMID: 35561319.

24: Radaelli S, Pasquali S, Colombo C, Callegaro D, Sanfilippo R, Stacchiotti S, Provenzano S, Sangalli C, Morosi C, Barisella M, Miceli R, Fiore M, Gronchi A. Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort. *Eur J Surg Oncol.* 2022 Aug;48(8):1723-1729. doi: 10.1016/j.ejso.2022.01.003. Epub 2022 Jan 21. PMID: 35153104.

25: Spolverato G, Chiminazzo V, Lorenzoni G, Fiore M, Radaelli S, Sanfilippo R, Sangalli C, Barisella M, Callegaro D, Gronchi A. Oncological outcomes after major vascular resections for primary retroperitoneal liposarcoma. *Eur J Surg Oncol.* 2021 Dec;47(12):3004-3010. doi: 10.1016/j.ejso.2021.06.035. Epub 2021 Jul 2. PMID: 34364722.

26: Mannarino L, Craparotta I, Ballabio S, Frapolli R, Meroni M, Bello E, Panini N, Callari M, Sanfilippo R, Casali PG, Barisella M, Fabbroni C, Marchini S, D'Incalci M. Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma. *Genomics.* 2021 Sep;113(5):3439-3448. doi: 10.1016/j.ygeno.2021.07.028. Epub 2021 Jul 30. Erratum in: *Genomics.* 2022 Jan;114(1):473. doi: 10.1016/j.ygeno.2021.09.005. PMID: 34339817.

27: Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleiner ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. *Cancer*. 2021 Aug 15;127(16):2934-2942. doi: 10.1002/cncr.33618. Epub 2021 Apr 28. PMID: 33910263; PMCID: PMC8319065.

28: Fabbroni C, Fucà G, Ligorio F, Fumagalli E, Barisella M, Collini P, Morosi C, Gronchi A, Dei Tos AP, Casali PG, Sanfilippo R. Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. *Cancers (Basel)*. 2021 Mar 22;13(6):1453. doi: 10.3390/cancers13061453. PMID: 33810165; PMCID: PMC8005098.

29: Palmerini E, Sanfilippo R, Grignani G, Buonadonna A, Romanini A, Badalamenti G, Ferraresi V, Vincenzi B, Comandone A, Pizzolorusso A, Brunello A, Gelsomino F, Pas T, Ibrahim T, Grosso F, Zanelli F, Pantaleo MA, Milesi L, Ciuffreda L, Ferrari V, Marchesi E, Quattrini I, Righi A, Setola E, Carretta E, Picci P, Ferrari S. Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. *Cancers (Basel)*. 2021 Mar 2;13(5):1053. doi: 10.3390/cancers13051053. PMID: 33801399; PMCID: PMC7958606.

30: Kasper B, Achee A, Schuster K, Wilson R, van Oortmerssen G, Gladdy RA, Hemming ML, Huang P, Ingham M, Jones RL, Pollack SM, Reinke D, Sanfilippo R, Schuetze SM, Somaiah N, Van Tine BA, Wilky B, Okuno S, Trent J. Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). *Cancers (Basel)*. 2021 Feb 20;13(4):886. doi: 10.3390/cancers13040886. PMID: 33672607; PMCID: PMC7924026.

31: Zuco V, Pasquali S, Tortoreto M, Brich S, Percio S, Dagrada GP, Colombo C, Sanfilippo R, Lauricella C, Gounder M, El Bezawy R, Barisella M, Dei Tos AP, Casali PG, Gronchi A, Stacchiotti S, Zaffaroni N. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. *J Exp Clin Cancer Res*. 2021 Mar 1;40(1):83. doi: 10.1186/s13046-021-01886-x. PMID: 33648535; PMCID: PMC7923610.

32: Tseng WW, Barretta F, Conti L, Grignani G, Tolomeo F, Albertsmeier M, Angele MK, Rutkowski P, Skoczylas J, De Paoli A, Navarria F, Raut CP, Fairweather M, Farma JM, Nessim C, Goel N, Grignol VP, Ford SJ, Cardona K, Subhawong T,

Tattersall HL, Lee RM, Hu JS, von Mehren M, Sanfilippo R, Gronchi A. Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. *Cancer*. 2021 Mar 1;127(5):729-738. doi: 10.1002/cncr.33323. Epub 2020 Nov 18. PMID: 33206381.

33: Ferrandina G, Aristei C, Biondetti PR, Cananzi FCM, Casali P, Ciccarone F, Colombo N, Comandone A, Corvo' R, De Iaco P, Dei Tos AP, Donato V, Fiore M, Franchi, Gadducci A, Gronchi A, Guerriero S, Infante A, Odicino F, Pirroni T, Quagliuolo V, Sanfilippo R, Testa AC, Zannoni GF, Scambia G, Lorusso D. Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). *Eur J Cancer*. 2020 Nov;139:149-168. doi: 10.1016/j.ejca.2020.08.016. Epub 2020 Sep 29. Erratum in: *Eur J Cancer*. 2021 Feb;144:397-398. doi: 10.1016/j.ejca.2020.11.001. PMID: 32992154.

34: Fucà G, Fabbroni C, Mancari R, Manglaviti S, Bogani G, Fumagalli E, Bertulli R, Morosi C, Collini P, Raspagliesi F, Colombo N, Casali PG, Sanfilippo R. Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers. *Clin Sarcoma Res*. 2020 Aug 28;10:17. doi: 10.1186/s13569-020-00139-3. PMID: 32874547; PMCID: PMC7456084.

35: Sanfilippo R, Fabbroni C, Fucà G, Fumagalli E, Morosi C, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors. *Clin Cancer Res*. 2020 Oct 15;26(20):5534-5538. doi: 10.1158/1078-0432.CCR-20-1191. Epub 2020 Jun 30. PMID: 32605908.

36: Fabbroni C, Sbaraglia M, Sanfilippo R. Medical treatment of advanced malignant perivascular epithelioid cell tumors. *Curr Opin Oncol*. 2020 Jul;32(4):301-306. doi: 10.1097/CCO.0000000000000649. PMID: 32541317.

37: D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litière S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *Cancer*. 2020 Jun 1;126(11):2637-2647. doi: 10.1002/cncr.32795. Epub 2020 Mar 4. PMID: 32129883.

38: Frapolli R, Bello E, Ponzo M, Craparotta I, Mannarino L, Ballabio S, Marchini S, Carrassa L, Ubezio P, Porcu L, Brich S, Sanfilippo R, Casali PG, Gronchi A, Pilotti S, D'Incalci M. Combination of PPAR γ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas. *Clin Cancer Res*. 2019 Dec 15;25(24):7565-7575. doi:

10.1158/1078-0432.CCR-19-0976. Epub 2019 Sep 3. Erratum in: Clin Cancer Res. 2020 Mar 1;26(5):1199. doi: 10.1158/1078-0432.CCR-20-0172. PMID: 31481505.

39: Bello E, Brich S, Craparotta I, Mannarino L, Ballabio S, Gatta R, Marchini S, Carrassa L, Matteo C, Sanfilippo R, Gronchi A, Casali PG, Pilotti S, D'Incalci M, Frapolli R. Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin. Br J Cancer. 2019 Sep;121(6):464-473. doi: 10.1038/s41416-019-0550-2. Epub 2019 Aug 14. Erratum in: Br J Cancer. 2020 Mar;122(7):1120. doi: 10.1038/s41416-020-0746-5. PMID: 31409911; PMCID: PMC6738121.

40: Nizri E, Fiore M, Barretta F, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Stacchiotti S, Casali PG, Miceli R, Gronchi A. Intraperitoneal Invasion of Retroperitoneal Sarcomas: A Risk Factor for Dismal Prognosis. Ann Surg Oncol. 2019 Oct;26(11):3535-3541. doi: 10.1245/s10434-019-07615-1. Epub 2019 Jul 16. PMID: 31313035.

41: Sanfilippo R, Jones RL, Blay JY, Le Cesne A, Provenzano S, Antoniou G, Mir O, Fucà G, Fumagalli E, Bertulli R, Stacchiotti S, Brahmi M, Grosso F, Dufresne A, Hindi N, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clin Cancer Res. 2019 Sep 1;25(17):5295-5300. doi: 10.1158/1078-0432.CCR-19-0288. Epub 2019 Jun 19. PMID: 31217199.

42: Gronchi A, Hindi N, Cruz J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Sanfilippo R, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, Martin-Broto J. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. EClinicalMedicine. 2019 Mar 11;9:35-43. doi: 10.1016/j.eclinm.2019.03.007. PMID: 31143880; PMCID: PMC6510725.

43: Nizri E, Fiore M, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Morosi C, Stacchiotti S, Casali PG, Gronchi A. Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients-A propensity score analysis. J Surg Oncol. 2019 Mar;119(3):318-323. doi: 10.1002/jso.25337. Epub 2018 Dec 16. PMID: 30554403.

44: Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, Fumagalli E, Gronchi A, Casali PG, Sanfilippo R. Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. Oncologist. 2019 Jul;24(7):e536-e541. doi: 10.1634/theoncologist.2018-0338. Epub 2018 Dec 5. PMID: 30518617; PMCID: PMC6656447.

45: Gadducci A, Grosso F, Scambia G, Raspagliesi F, Colombo N, Grignani G, Casali P, Sanfilippo R, Buonadonna A, Santoro A, Bruzzzone M, Artioli G, Lorusso D, Biagioli E, Fossati R, Galli F, Negri E, Rulli E, Torri V, D'Incalci M. A

phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. *Br J Cancer*. 2018 Aug;119(5):565-571. doi: 10.1038/s41416-018-0190-y. Epub 2018 Jul 30. PMID: 30057406; PMCID: PMC6162262.

46: Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Fonatella C, Sanfilippo R, Leone Roberti Maggiore U, Ferrero S, Lorusso D, Raspagliesi F. Role of bevacizumab in uterine leiomyosarcoma. *Crit Rev Oncol Hematol*. 2018 Jun;126:45-51. doi: 10.1016/j.critrevonc.2018.03.019. Epub 2018 Mar 29. PMID: 29759566.

47: De Sanctis R, Giordano L, Colombo C, De Paoli A, Navarria P, Sangalli C, Buonadonna A, Sanfilippo R, Bertola G, Fiore M, Marrari A, Navarria F, Bertuzzi A, Casali PG, Basso S, Santoro A, Quagliuolo V, Gronchi A. Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303. *Ann Surg Oncol*. 2017 Dec;24(13):3872-3879. doi: 10.1245/s10434-017-6105-y. Epub 2017 Oct 17. PMID: 29043525.

48: Colia V, Fumagalli E, Provenzano S, Bertulli R, Stacchiotti S, Morosi C, Collini P, Gronchi A, Casali PG, Sanfilippo R. High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. *Sarcoma*. 2017;2017:3739159. doi: 10.1155/2017/3739159. Epub 2017 Aug 30. PMID: 28947876; PMCID: PMC5602616.

49: Colia V, Fiore M, Provenzano S, Fumagalli E, Bertulli R, Morosi C, Dei Tos AP, Barisella M, Gronchi A, Casali PG, Sanfilippo R. Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. *Clin Sarcoma Res*. 2017 Aug 22;7:16. doi: 10.1186/s13569-017-0082-6. PMID: 28852467; PMCID: PMC5568720.

50: Gelderblom H, Judson IR, Benson C, Merimsky O, Grignani G, Katz D, Freivogel KW, Stein D, Jobanputra M, Mungul A, Manson SC, Sanfilippo R. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study. *Acta Oncol*. 2017 Dec;56(12):1769-1775. doi: 10.1080/0284186X.2017.1332779. Epub 2017 Jul 19. PMID: 28723233.

51: Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, Tonini G. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. *Br J Cancer*. 2017 Jul 25;117(3):340-346. doi: 10.1038/bjc.2017.187. Epub 2017 Jun 22. PMID: 28641307; PMCID: PMC5537497.

52: Radaelli S, Fiore M, Colombo C, Ford S, Palassini E, Sanfilippo R, Stacchiotti S, Sangalli C, Morosi C, Casali PG, Gronchi A. Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. *Surg Oncol*. 2016 Sep;25(3):125-31. doi: 10.1016/j.suronc.2016.05.002. Epub 2016 May 7. PMID:

27566012.

53: Callegaro D, Miceli R, Brunelli C, Colombo C, Sanfilippo R, Radaelli S, Casali PG, Caraceni A, Gronchi A, Fiore M. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. *Br J Surg*. 2015 Aug;102(9):1079-87. doi: 10.1002/bjs.9829. Epub 2015 Jun 3. PMID: 26041724.

54: Coens C, van der Graaf WT, Blay JY, Chawla SP, Judson I, Sanfilippo R, Manson SC, Hodge RA, Marreaud S, Prins JB, Lugowska I, Litière S, Bottomley A. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). *Cancer*. 2015 Sep 1;121(17):2933-41. doi: 10.1002/cncr.29426. Epub 2015 May 29. PMID: 26033286.

55: Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le Cesne A, Benson C, Vizzini L, Contu M, Baldi GG, Dei Tos AP, Casali PG. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. *Anticancer Drugs*. 2015 Jul;26(6):678-81. doi: 10.1097/CAD.0000000000000228. PMID: 25763543; PMCID: PMC4730787.

56: Hristova I, Boellaard R, Vogel W, Mottaghy F, Marreaud S, Collette S, Schöffski P, Sanfilippo R, Dewji R, van der Graaf W, Oyen WJ. Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. *Eur J Nucl Med Mol Imaging*. 2015 May;42(6):848-57. doi: 10.1007/s00259-015-3002-0. Epub 2015 Feb 25. PMID: 25711176; PMCID: PMC4382532.

57: Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C, Messina A, Dei Tos AP, Gronchi A, Casali PG. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. *Clin Sarcoma Res*. 2014 Nov 22;4(1):16. doi: 10.1186/2045-3329-4-16. PMID: 25628856; PMCID: PMC4307996.

58: Laroche-Clary A, Chaire V, Le Morvan V, Neuville A, Bertucci F, Salas S, Sanfilippo R, Pourquier P, Italiano A. BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. *Br J Cancer*. 2015 Feb 17;112(4):688-92. doi: 10.1038/bjc.2014.624. Epub 2015 Jan 20. PMID: 25602962; PMCID: PMC4333490.

59: Gronchi A, Collini P, Miceli R, Valeri B, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, Casali PG, Dei Tos AP, Pilotti S. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. *Am J Surg Pathol*. 2015 Mar;39(3):383-93. doi: 10.1097/PAS.0000000000000366. PMID: 25581729.

60: Morosi C, Stacchiotti S, Marchianò A, Bianchi A, Radaelli S, Sanfilippo R, Colombo C, Richardson C, Collini P, Barisella M, Casali PG, Gronchi A, Fiore M.

Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: analysis of 291 consecutive patients at a tertiary reference sarcoma center. *Eur J Surg Oncol.* 2014 Dec;40(12):1662-70. doi: 10.1016/j.ejso.2014.10.005. Epub 2014 Oct 15. PMID: 25454827.

61: Gronchi A, Miceli R, Allard MA, Callegaro D, Le Péchoux C, Fiore M, Honoré C, Sanfilippo R, Coppola S, Stacchiotti S, Terrier P, Casali PG, Le Cesne A, Mariani L, Colombo C, Bonvalot S. Personalizing the approach to retroperitoneal soft tissue sarcoma: histology-specific patterns of failure and postrelapse outcome after primary extended resection. *Ann Surg Oncol.* 2015 May;22(5):1447-54. doi: 10.1245/s10434-014-4130-7. Epub 2014 Oct 10. PMID: 25300609.

62: De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada G, Disciglio V, Sanfilippo R, Gronchi A, D'Incalci M, Casali PG, Canevari S, Pierotti MA, Pilotti S. Identification of a gene expression driven progression pathway in myxoid liposarcoma. *Oncotarget.* 2014 Aug 15;5(15):5965-77. doi: 10.18632/oncotarget.2023. PMID: 25115389; PMCID: PMC4171605.

63: Dossi R, Frapolli R, Di Giandomenico S, Paracchini L, Bozzi F, Brich S, Castiglioni V, Borsotti P, Belotti D, Ubaldi S, Sanfilippo R, Erba E, Giavazzi R, Marchini S, Pilotti S, D'Incalci M, Taraboletti G. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. *Int J Cancer.* 2015 Feb 1;136(3):721-9. doi: 10.1002/ijc.29023. Epub 2014 Jun 19. PMID: 24917554.

64: Stacchiotti S, Dagrada GP, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, Gronchi A, Dei Tos AP, Pilotti S, Casali PG. Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. *Clin Sarcoma Res.* 2013 Dec 18;3(1):16. doi: 10.1186/2045-3329-3-16. PMID: 24345066; PMCID: PMC3879193.

65: Gronchi A, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, Bertola G, Navarria P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorrello L, Fiore M, Bruzzi P, Casali PG. Preoperative chemoradiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. *Eur J Cancer.* 2014 Mar;50(4):784-92. doi: 10.1016/j.ejca.2013.11.021. Epub 2013 Dec 5. PMID: 24316063.

66: Di Giandomenico S, Frapolli R, Bello E, Ubaldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, Gronchi A, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JM, D'Incalci M. Mode of action of trabectedin in myxoid liposarcomas. *Oncogene.* 2014 Oct 30;33(44):5201-10. doi: 10.1038/onc.2013.462. Epub 2013 Nov 11. PMID: 24213580.

67: Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollè G, Sanfilippo R, Gronchi A, Perrone F, Tamborini E, Pelosi G, Pierotti MA, Maestro R, Pricl S, Pilotti S. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/differentiated liposarcomas. *Lab Invest.* 2013

Nov;93(11):1232-40. doi: 10.1038/labinvest.2013.107. Epub 2013 Sep 9. PMID: 24018792.

68: Ditto A, Martinelli F, Carcangiu M, Solima E, de Carrillo KJ, Sanfilippo R, Haeusler E, Raspagliesi F. Embryonal rhabdomyosarcoma of the uterine cervix in adults: a case report and literature review. *J Low Genit Tract Dis*. 2013 Oct;17(4):e12-7. doi: 10.1097/LGT.0b013e31827a8b8c. PMID: 23903199.

69: Sanfilippo R, Dei Tos AP, Casali PG. Myxoid liposarcoma and the mammalian target of rapamycin pathway. *Curr Opin Oncol*. 2013 Jul;25(4):379-83. doi: 10.1097/CCO.0b013e32836227ac. PMID: 23673410.

70: Sanfilippo R, Casali PG. The intriguing patterns of tumor response to trabectedin. *Expert Rev Anticancer Ther*. 2013 Jun;13(6 Suppl 1):21-4. doi: 10.1586/era.13.51. PMID: 23638727.

71: Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Ubaldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P. Role of macrophage targeting in the antitumor activity of trabectedin. *Cancer Cell*. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008. PMID: 23410977.

72: Mandalà M, Grosso F, Vitalini C, Corradino I, Sanfilippo R, Colombini S, Clerici M, Labianca R, De Pascale A, Marsoni S. Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies. *Br J Cancer*. 2012 Aug 7;107(4):612-6. doi: 10.1038/bjc.2012.325. Epub 2012 Jul 24. PMID: 22828607; PMCID: PMC3419966.

73: Casali PG, Sanfilippo R. Uterine sarcomas: a multidisciplinary challenge. *Eur J Cancer*. 2011 Sep;47 Suppl 3:S326-7. doi: 10.1016/S0959-8049(11)70189-7. PMID: 21944001.

74: Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, Dei Tos AP, Raspagliesi F, Judson I, Casali PG. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. *Gynecol Oncol*. 2011 Dec;123(3):553-6. doi: 10.1016/j.ygyno.2011.08.016. Epub 2011 Sep 13. PMID: 21917307.

75: Gronchi A, Miceli R, Colombo C, Stacchiotti S, Collini P, Mariani L, Sangalli C, Radaelli S, Sanfilippo R, Fiore M, Casali PG. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. *Ann Oncol*. 2012 Apr;23(4):1067-73. doi: 10.1093/annonc/mdr323. Epub 2011 Jul 16. PMID: 21765179.

76: Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S, Morosi C, Dei Tos AP, Pilotti S, Casali PG. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. *Ann Oncol*. 2012 Feb;23(2):501-8. doi: 10.1093/annonc/mdr066. Epub 2011 Apr 4. PMID: 21464156.

77: Italiano A, Laurand A, Laroche A, Casali P, Sanfilippo R, Le Cesne A, Judson I, Blay JY, Ray-Coquard I, Bui B, Coindre JM, Nieto A, Tercero JC, Jimeno J, Robert J, Pourquier P. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. *Cancer*. 2011 Aug 1;117(15):3445-56. doi: 10.1002/cncr.25925. Epub 2011 Feb 1. PMID: 21287534.

78: Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E, Barisella M, Sangalli C, Mariani L, Casali PG, Gronchi A. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Ann Surg Oncol*. 2011 Mar;18(3):720-5. doi: 10.1245/s10434-010-1341-4. Epub 2010 Sep 28. PMID: 20878245.

79: Frapolli R, Tamborini E, Viridis E, Bello E, Tarantino E, Marchini S, Grosso F, Sanfilippo R, Gronchi A, Tercero JC, Peloso G, Casali P, Pilotti S, D'Incalci M. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors. *Clin Cancer Res*. 2010 Oct 15;16(20):4958-67. doi: 10.1158/1078-0432.CCR-10-0317. Epub 2010 Aug 20. PMID: 20732964.

80: Negri T, Viridis E, Brici S, Bozzi F, Tamborini E, Tarantino E, Jocolle G, Cassinelli G, Grosso F, Sanfilippo R, Casalini P, Greco A, Pierotti MA, Pilotti S. Functional mapping of receptor tyrosine kinases in myxoid liposarcoma. *Clin Cancer Res*. 2010 Jul 15;16(14):3581-93. doi: 10.1158/1078-0432.CCR-09-2912. Epub 2010 Jun 3. PMID: 20522586.

81: Casali PG, Sanfilippo R, D'Incalci M. Trabectedin therapy for sarcomas. *Curr Opin Oncol*. 2010 Jul;22(4):342-6. doi: 10.1097/CCO.0b013e32833aaac1. PMID: 20489618.

82: Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Viridis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. *Cancer Res*. 2010 Mar 15;70(6):2235-44. doi: 10.1158/0008-5472.CAN-09-2335. Epub 2010 Mar 9. PMID: 20215499.

83: Grosso F, Sanfilippo R, Viridis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Pilotti S, Casali PG. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. *Ann Oncol*. 2009 Aug;20(8):1439-44. doi: 10.1093/annonc/mdp004. Epub 2009 May 22. PMID: 19465423.

84: Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. *Lancet Oncol*. 2007 Jul;8(7):595-602. doi: 10.1016/S1470-2045(07)70175-4. PMID: 17586092.

85: Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, Bertulli R, Piovesan C, Jimeno J, D'Incalci M, Gescher A, Casali PG. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer. 2006 Jul;42(10):1484-90. doi: 10.1016/j.ejca.2006.02.010. Epub 2006 Jun 5. PMID: 16737808.

D. Research Support

Ongoing Research Support

2020-ongoing	Granting Agency: AIRC (Italian Association for Cancer Research), Title: Enhancement of trabectedin efficacy and trabectedin-induced adipocytic differentiation in liposarcomas by PPAR γ agonists	Role: collaborator
--------------	--	--------------------

Milan, September 11, 2023